Evidence map›Paper›PMID 33329548›Full record

ArticleFrontiers in immunology2020

Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature.

Tiina Kelkka, Paula Savola, Dipabarna Bhattacharya, Jani Huuhtanen, Tapio Lönnberg, Matti Kankainen, Kirsi Paalanen, Mikko Tyster, Maija Lepistö, Pekka Ellonen and 13 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 9 institutions in 2 countries.

Tiina KelkkaHematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.
Paula SavolaHematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.
Dipabarna BhattacharyaHematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.
Jani HuuhtanenHematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.
Tapio LönnbergTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Matti KankainenHematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.
Kirsi PaalanenRheumatology, Jyväskylä Central Hospital, Jyväskylä, Finland.
Mikko TysterHematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.
Maija LepistöInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Pekka EllonenInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Johannes SmolanderTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Samuli EldforsInstitute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Bhagwan YadavHematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.
Sofia KhanTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Riitta KoivuniemiRheumatology, University of Helsinki, Helsinki University Hospital, Helsinki, Finland.
Christopher SjöwallDepartment of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden.
Laura L EloTurku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Harri LähdesmäkiDepartment of Computer Science, Aalto University School of Science, Espoo, Finland.
Yuka MaedaDivision of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Japan.
Hiroyoshi NishikawaDivision of Cancer Immunology, Research Institute/Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Tokyo, Japan.
Marjatta Leirisalo-RepoRheumatology, University of Helsinki, Helsinki University Hospital, Helsinki, Finland.
Tuulikki Sokka-IslerRheumatology, Jyväskylä Central Hospital, Jyväskylä, Finland.
Satu MustjokiHematology Research Unit Helsinki, University of Helsinki, Helsinki, Finland.
University of Helsinki · FIHelsinki University Hospital · FIÅbo Akademi University · FIInstitute for Molecular Medicine Finland · FIAalto University · FICentral Finland Health Care District · FILinköping University · SETurku Centre for Computer Science · FIUniversity of Eastern Finland · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a complex autoimmune disease targeting synovial joints. Traditionally, RA is divided into seropositive (SP) and seronegative (SN) disease forms, the latter consisting of an array of unrelated diseases with joint involvement. Recently, we described a severe form of SN-RA that associates with characteristic joint destruction. Here, we sought biological characteristics to differentiate this rare but aggressive anti-citrullinated peptide antibody-negative destructive RA (CND-RA) from early seropositive (SP-RA) and seronegative rheumatoid arthritis (SN-RA). We also aimed to study cytotoxic CD8+ lymphocytes in autoimmune arthritis. CND-RA, SP-RA and SN-RA were compared to healthy controls to reveal differences in T-cell receptor beta (TCRβ) repertoire, cytokine levels and autoantibody repertoires. Whole-exome sequencing (WES) followed by single-cell RNA-sequencing (sc-RNA-seq) was performed to study somatic mutations in a clonally expanded CD8+ lymphocyte population in an index patient. A unique TCRβ signature was detected in CND-RA patients. In addition, CND-RA patients expressed higher levels of the bone destruction-associated TNFSF14 cytokine. Blood IgG repertoire from CND-RA patients recognized fewer endogenous proteins than SP-RA patients' repertoires. Using WES, we detected a stable mutation profile in the clonally expanded CD8+ T-cell population characterized by cytotoxic gene expression signature discovered by sc-RNA-sequencing. Our results identify CND-RA as an independent RA subset and reveal a CND-RA specific TCR signature in the CD8+ lymphocytes. Improved classification of seronegative RA patients underlines the heterogeneity of RA and also, facilitates development of improved therapeutic options for the treatment resistant patients.

Indexed as

Genes, T-Cell ReceptorTranscriptomeAdolescentAdultAgedAnti-Citrullinated Protein AntibodiesArthritis, RheumatoidBiomarkersCase-Control StudiesCytokinesExome SequencingFemaleGene Expression ProfilingHumansMaleMiddle AgedAnti-Citrullinated Protein AntibodiesBiomarkersCytokinesACPA-negativeCD8+ lymphocyterheumatoid arthritisseronegativesomatic mutationT cell receptor

Identifiers

PMID33329548
PMCPMC7732449
OpenAlexW3107555362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.